In another study, Han et al. identified a stem-like PCa subtype of metastatic castration-resistant prostate cancer that arose from AR-positive cells as a consequence of its blockade with enzalutamide and therapy-induced lineage plasticity (Han et al., 2022). The gene discussed is AR; the disease is posterior cortical atrophy.